Efficacy and safety of Mirikizumab, a p19-selective IL-23 inhibitor, vs. Ustekinumab in moderate to severe CD: IBDnet

Title: Efficacy and safety of Mirikizumab, a p19-selective IL-23 inhibitor, vs. Ustekinumab in moderate to severe CD
Study drug: Mirkizumab
Sponsor: Eli-Lilly
Participating centers and contact: Insel Bern, PD Dr. med. Pascal Juillerat (Pascal.Juillerat@insel.ch)
Target population: Moderate to severe CD
Primary outcome:
Inclusion criteria:
Exclusion criteria:
More information:

Efficacy and safety of Mirikizumab, a p19-selective IL-23 inhibitor, vs. Ustekinumab in moderate to severe CD